Recombinant Human MARCO Protein, N-His-SUMO from ProteoGenix; catalogue ARO-P11567; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Human MARCO Protein is a type of recombinant protein that plays a crucial role in the immune system. It is a transmembrane receptor protein that is expressed on the surface of macrophages, which are a type of white blood cell responsible for engulfing and destroying foreign particles in the body. This protein is involved in various immune responses and has been extensively studied for its structure, activity, and potential applications.
The human MARCO gene is located on chromosome 2 and encodes for a protein with a molecular weight of approximately 75 kDa. The protein consists of 522 amino acids and has a typical structure of a scavenger receptor, with a large extracellular domain, a transmembrane domain, and a short cytoplasmic tail. The extracellular domain contains a ligand-binding region, while the cytoplasmic tail contains signaling motifs that are involved in the activation of downstream signaling pathways.
MARCO protein is primarily expressed on the surface of macrophages, where it plays a key role in the recognition and binding of various foreign particles, such as bacteria, viruses, and other pathogens. This binding triggers a signaling cascade that leads to the activation of the macrophage and the subsequent engulfment and destruction of the foreign particle. This process is crucial for the immune system’s ability to defend against infections and diseases.
In addition to its role in immune responses, MARCO protein has also been shown to be involved in other cellular processes, such as phagocytosis, cell adhesion, and inflammation. It has been reported that MARCO protein can also act as a pattern recognition receptor, recognizing specific molecular patterns on the surface of pathogens and triggering an immune response.
Due to its crucial role in immune responses, Recombinant Human MARCO Protein has been studied extensively for its potential applications in various fields. One of the main applications of this protein is in the development of vaccines. By using MARCO protein as an antigen, researchers have been able to induce a strong immune response against specific pathogens, leading to the development of effective vaccines. This has been particularly useful in the development of vaccines against bacterial infections, such as tuberculosis and pneumonia.
In addition to its use in vaccine development, Recombinant Human MARCO Protein has also been studied for its potential in cancer therapy. It has been reported that MARCO protein is highly expressed on the surface of certain types of cancer cells, making it a potential target for cancer treatment. By using MARCO protein as a target, researchers have been able to develop targeted therapies that specifically target cancer cells, while sparing healthy cells.
Moreover, Recombinant Human MARCO Protein has also been studied for its potential in the diagnosis and treatment of various inflammatory diseases, such as rheumatoid arthritis and atherosclerosis. By targeting MARCO protein, researchers have been able to develop diagnostic tools and therapies that can specifically target and modulate the inflammatory response, leading to improved treatment outcomes.
In conclusion, Recombinant Human MARCO Protein is a vital component of the immune system, playing a crucial role in immune responses and other cellular processes. Its unique structure and activity make it a promising target for various applications, including vaccine development, cancer therapy, and treatment of inflammatory diseases. Further research and development in this field will undoubtedly lead to the discovery of new and innovative ways to utilize this protein for the benefit of human health.
ProteoGenix catalogue number ARO-P11567. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 23.37 kDa; Fragment: Ser421-Val520; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
